Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Pharma Licenses ChemAxon Software for Drug R&D

Premium

ChemAxon said this week that Eisai, a Japanese pharmaceutical company, has licensed one of its cheminformatics packages through its distributor Patcore, an informatics services company based in Japan.

Specifically, Eisai will use ChemAxon's JChem Cartridge, a chemical database management and search tool, to manage the compound structure information it generates in its drug discovery efforts, ChemAxon said.

JChem Cartridge will be used alongside a compound control checking system developed by Patcore called CRAIS Checker, which evaluates chemical structures to determine whether compounds are controlled substances.

In December, ChemAxon announced that it had moved its headquarters to a larger office in its hometown of Budapest, Hungary. The company said that the move would help it better meet the needs of its growing customer base as well as house existing staff and new hires (BI 12/9/2011).

Shortly afterwards, ChemAxon said that it would be working along with its partner Linguamatics on a €671,000 ($870,000) EU-funded project, dubbed Chemically Informed Knowledge Extraction from Literature, or ChiKEL, that aims to develop text-mining software for chemical research (BI 12/16/2011).

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.